Seer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples

Rhea-AI Summary

Seer (Nasdaq: SEER) will provide its Proteograph product suite to deeply profile the plasma proteome in 10,000 PRECISE-SG100K participant samples, integrated with Thermo Fisher Olink Reveal and Orbitrap Astral data.

The collaboration aims to add deep, unbiased proteomics to a ~100,000-person, multi-ancestry Singapore cohort to support biomarker discovery, drug target biology, and population-level risk models.

Market Context

This announcement highlights Seer’s role in a major precision-health effort, applying its Proteograp...

Analysis

This announcement highlights Seer’s role in a major precision-health effort, applying its Proteograph platform to 10,000 samples within the PRECISE-SG100K cohort of about 100,000 residents. It reinforces the company’s focus on deep, unbiased proteomics in population-scale studies, building on prior IP validation and an installed base of 82 instruments. Investors may track how such collaborations contribute to revenue growth, margins, and follow-on adoption across additional large-scale cohorts.

Key Figures

Proteomics samples: 10,000 participants Cohort size: 100,000 residents Upheld patent claims: 23 claims +5 more

8 metrics

Proteomics samples 10,000 participants PRECISE-SG100K plasma proteome profiling with Proteograph

Cohort size 100,000 residents Approximate multi-ancestry PRECISE-SG100K population

Upheld patent claims 23 claims ’360 Proteograph enrichment patent claims upheld by PTAB

IP portfolio size 240+ patents Issued and pending patents supporting Proteograph platform

Q4 2025 revenue $4.2M Fourth quarter 2025 results

FY 2025 revenue $16.6M Full year 2025 results

Year-end cash $240.6M Cash, cash equivalents and investments at Dec 31, 2025

Instruments installed 82 instruments Installed base of Proteograph systems at year-end 2025

Historical Context

5 past events · Latest: Mar 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 30	Patent decision	Positive	+1.2%	PTAB upheld 23 claims on core Proteograph enrichment patent.
Mar 04	Activist letter	Negative	+2.8%	Radoff-JEC group criticized governance, sending open letter to directors.
Feb 26	Tax NOL plan	Positive	-17.3%	Adopted plan to protect about $262M of NOLs via ownership limits.
Feb 26	Earnings update	Negative	-17.3%	Reported 2025 results with continued losses and modest 3% 2026 growth outlook.
Feb 23	Activist pressure	Negative	+4.0%	Activist group owning ~7.5% demanded significant strategic and governance changes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often drew sharp reactions, with governance and tax-related items seeing larger moves than operational updates.

Recent Company History

Over the last few months, Seer reported several notable developments. On Feb 26, 2026 it posted Q4 and full-year 2025 results, with $4.2M in Q4 revenue and $16.6M for 2025, alongside ongoing losses and cautious 2026 guidance. Activist investors, owning about 7.5%, pressed for governance and operational changes in a Feb 23 letter. The company also adopted a tax benefit preservation plan to protect roughly $262M of NOLs. Most recently, on Mar 23, the patent board upheld 23 key Proteograph claims, reinforcing its IP around deep proteomics.

Key Terms

proteomics, mass spectrometry, multi-omic, genomic, +4 more

8 terms

proteomics medical

"Seer’s Proteograph will be used to generate enhanced proteomic insights..."

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

mass spectrometry technical

"selected as the mass spectrometry-based proteomic workflow to deeply profile..."

Mass spectrometry is a laboratory technique that identifies and measures chemicals by giving molecules an electrical charge and sorting them by how fast they move, like weighing and separating coins to see which kinds are present. For investors, its results are evidence used in drug development, quality control, food and environmental testing, and diagnostics, so clear mass-spec data can affect regulatory approval, product reliability, costs and market confidence.

multi-omic medical

"one of the world’s largest multi-omic health studies..."

Multi-omic describes the combined analysis of different biological data types—such as genes, proteins and small molecules—to get a fuller picture of how living systems work. Think of it like studying a recipe (genes), the ingredients list (proteins) and the final dish (metabolites) together rather than separately. For investors, multi-omic approaches can improve drug discovery, diagnostics and patient targeting, potentially raising the odds of successful, marketable products.

genomic medical

"designed to integrate genomic, proteomic, and other health data..."

Relating to an organism’s genome — the complete set of DNA instructions that determine traits and biological functions — and to the study or use of that information. For investors, genomic technologies and data underpin diagnostics, targeted medicines, and personalized treatments, shaping potential market size, product timelines, and regulatory risk; think of it as reading an instruction manual to design precise medical products, which can speed innovation but also bring scientific and approval uncertainty.

biomarkers medical

"central to validating biomarkers, understanding drug targets..."

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

drug targets medical

"validating biomarkers, understanding drug targets, and building population-level..."

A drug target is a molecule in the body—often a protein, receptor or gene—that a medicine is designed to interact with to change a disease process. Think of it as a lock and the drug as the key: a well-chosen lock makes the key more likely to work, be safe, and be patentable. Investors care because the nature and validation of a target strongly affect a drug’s chances of success, development costs, regulatory risk and potential market value.

affinity-based platforms technical

"extend signals detected by affinity-based platforms such as Olink Reveal..."

Affinity-based platforms are online or service networks built around a shared identity, interest, profession, or relationship—like alumni groups, hobby communities, or employee benefits programs—that connect members, offer tailored products or content, and often facilitate transactions. For investors, these platforms matter because their focused audiences can produce higher engagement, loyalty, and predictable revenue from memberships, targeted marketing, or specialized services, much like a neighborhood store that knows its customers’ needs and sells to them consistently.

population-scale medical

"becomes the mainstay for population-scale multi-omic studies..."

Population-scale describes a product, service, study or program designed to operate across very large groups of people—often millions—rather than a small pilot or individual use. For investors it signals potential for much larger revenue and cost implications, greater infrastructure and regulatory demands, and bigger impact on market adoption; think of it as the difference between a local shop and a nationwide chain.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Seer’s Proteograph will be used to generate enhanced proteomic insights in one of the world’s largest multi-omic health studies

REDWOOD CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph^® Product Suite, has been selected as the mass spectrometry-based proteomic workflow to deeply profile the plasma proteome in 10,000 participants from PRECISE-SG100K. This unbiased proteomics data set will be combined with data from Thermo Fisher Scientific’s Olink® Reveal and Thermo Scientific Orbitrap Astral™ mass spectrometers, utilized on the same set of samples to enhance the proteomic insights available to researchers.

PRECISE-SG100K is a landmark, multi-ancestry population-scale cohort of approximately 100,000 Singapore residents. It is designed to integrate genomic, proteomic, and other health data across a deeply phenotyped, multi-ancestry Asian population. By deploying Seer’s Proteograph platform alongside other genomic, imaging, and phenotyping technologies, PRECISE-SG100K aims to be one of the world’s most comprehensive multi-omic datasets to advance precision health, disease prevention and therapeutic discovery. Incorporating deep, unbiased plasma proteomics into a cohort of this scale creates a mechanistic layer that links genetic variation, protein networks, and clinical outcomes, which is central to validating biomarkers, understanding drug targets, and building population-level risk models.

The Proteograph–Astral combination has demonstrated high-throughput, deep proteome coverage in large population studies, providing thousands of quantified proteins with peptide-level resolution. This approach strengthens the ability of mass spectrometry-based proteomics to validate and extend signals detected by affinity-based platforms such as Olink Reveal and is increasingly regarded as an essential complement to affinity-based methods in large-scale proteomic studies.

“PRECISE-SG100K is one of the most ambitious and carefully designed multi-omic health initiatives in the world,” said Omid Farokhzad, Chair and CEO of Seer. “Seer’s Proteograph was built with the vision that deep, unbiased proteomics becomes the mainstay for population-scale multi-omic studies, and PRECISE-SG100K is the evidence of the emergence of that shift.

“A key goal of PRECISE-SG100K is to create a deeply characterized, multi-ancestry resource that can reveal how genetics, environment and lifestyle shape disease risk and treatment response,” said John Chambers, Chief Scientific Officer of PRECISE and Lead PI of PRECISE-SG100K study. “By adding deep, unbiased plasma proteomics enabled by Seer and Thermo Fisher, we can more directly link genomic variation to protein networks and health outcomes, uncovering insights critical to ensuring precision medicine reflects the diversity of Asian populations.”

Proteomics data generated with the Proteograph in population-scale cohorts like PRECISE-SG100K and Korea University are expected to support biomarker discovery across cardiometabolic, ophthalmic, neurologic and other complex diseases; advance drug target biology; inform predictive models for disease risk and response in underrepresented populations; and provide an orthogonal framework for validating and prioritizing markers identified through affinity-based platforms.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the throughput and complexity limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio

About PRECISE-SG100K Study

The PRECISE-SG100K study is a landmark long-term research project that has successfully completed its recruitment phase, having engaged over 100,000 participants from Singapore's diverse, multi-ethnic population. This comprehensive study has collected extensive baseline health information and biological specimens from participants across the nation. Moving forward, the study will continue to monitor long-term health outcomes and identify environmental, lifestyle and genetic factors associated with diseases such as diabetes, hypertension, and cancer. As one of the largest population health studies in Southeast Asia, PRECISE-SG100K represents a significant milestone for health research in Singapore and is positioned to yield globally significant results that will advance precision medicine and improve health outcomes for diverse populations worldwide. For more information, please visit Phase II: PRECISE SG100K

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s expectations about the collaboration with Precision Health Research and population-scale studies and the impact of the Seer’s products. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. 

Media Contact:

Patrick Schmidt
pr@seer.bio

Investor Contact:

Marissa Bych
investor@seer.bio

FAQ

What is Seer (SEER) supplying to the PRECISE-SG100K study?

Seer will supply its Proteograph product suite to generate deep, unbiased plasma proteomics on 10,000 samples. According to the company, Proteograph data will be integrated with Thermo Fisher Olink Reveal and Orbitrap Astral results to enhance proteomic insights.

How many PRECISE-SG100K samples will use Seer Proteograph for proteomics?

Proteomics will be performed on 10,000 PRECISE-SG100K participant samples using Seer's Proteograph. According to the company, these data will complement other multi-omic assays in the ~100,000-person cohort.

What research outcomes could Seer (SEER) Proteograph enable in PRECISE-SG100K?

Proteograph is expected to support biomarker discovery and drug target biology across cardiometabolic, neurologic, ophthalmic diseases. According to the company, it provides peptide-level resolution to link genetics and clinical outcomes.

How does Seer’s proteomics complement Thermo Fisher assays in PRECISE-SG100K?

Mass spectrometry-based Proteograph data offer an orthogonal, peptide-level validation to affinity-based Olink Reveal assays. According to the company, the combination strengthens signal validation and extends proteomic coverage.

Will Seer’s involvement in PRECISE-SG100K affect its research partnerships?

Seer’s selection for 10,000 samples signals expanded collaboration with large population studies and Thermo Fisher. According to the company, this deployment showcases Proteograph’s role in population-scale multi-omic initiatives.

What populations does PRECISE-SG100K target and why is that relevant to SEER?

PRECISE-SG100K targets a multi-ancestry Asian population of ~100,000 Singapore residents, enabling diverse proteomic insights. According to the company, this helps build risk models and validate biomarkers relevant to underrepresented populations.